LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN), the drug giant, Monday announced that its wholly-owned subsidiary Glaxo Group Limited, or GSK, will receive a 25.4% minority equity stake, representing a GBP1,250,000 investment, in Autifony Therapeutics Limited, a U.K.-based biotechnology start up created through a funding round of up to GBP10 million alongside investors Imperial Innovations and SV Life Sciences.
MAIN FACTS:
-Under the terms of the agreement, Autifony will issue 850,000 A ordinary shares to GSK in exchange for a number of pre-candidate voltage-gated ion channel modulator compounds and associated patent applications and data for development in hearing loss, as well as 571,429 Series A preferred shares in recognition of GBP400,000 worth of development work funded by GSK on behalf of Autifony.
-GSK will also be eligible to receive a further 550,000 A ordinary shares on achievement of a pre-determined milestone, at which time there will be a further investment by the existing consortium and GSK will then own 13.2% of Autifony on a fully diluted basis.
-GlaxoSmithKline PLC shares closed Friday at GBP12.43 valuing the company at GBP63.22 billion.
MAIN FACTS:
-Under the terms of the agreement, Autifony will issue 850,000 A ordinary shares to GSK in exchange for a number of pre-candidate voltage-gated ion channel modulator compounds and associated patent applications and data for development in hearing loss, as well as 571,429 Series A preferred shares in recognition of GBP400,000 worth of development work funded by GSK on behalf of Autifony.
-GSK will also be eligible to receive a further 550,000 A ordinary shares on achievement of a pre-determined milestone, at which time there will be a further investment by the existing consortium and GSK will then own 13.2% of Autifony on a fully diluted basis.
-GlaxoSmithKline PLC shares closed Friday at GBP12.43 valuing the company at GBP63.22 billion.
